David J. Kuter

22.4k total citations · 4 hit papers
214 papers, 10.4k citations indexed

About

David J. Kuter is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, David J. Kuter has authored 214 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Hematology, 76 papers in Genetics and 32 papers in Immunology. Recurrent topics in David J. Kuter's work include Platelet Disorders and Treatments (138 papers), Blood groups and transfusion (98 papers) and Chronic Lymphocytic Leukemia Research (54 papers). David J. Kuter is often cited by papers focused on Platelet Disorders and Treatments (138 papers), Blood groups and transfusion (98 papers) and Chronic Lymphocytic Leukemia Research (54 papers). David J. Kuter collaborates with scholars based in United States, United Kingdom and Germany. David J. Kuter's co-authors include Hanny Al‐Samkari, Klaus Weber, Junzhi Li, Yuping Xia, C. Glenn Begley, James B. Bussel, Amy M. Bertino, Roger M. Lyons, Rachel Rosovsky and Katayoon Goodarzi and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

David J. Kuter

205 papers receiving 10.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

2020 855 citations Hanny Al‐Samkari, Sunny Dzik et al. Blood profile →
American Society of Hematology 2019 guidelines for immune thrombocytopenia

2019 730 citations Cindy Neunert, Deirdra R. Terrell et al. Blood Advances profile →
Reversible Denaturation of Enzymes by Sodium Dodecyl Sulfate

1971 388 citations David J. Kuter et al. profile →
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

2019 286 citations Wilma Barcellini, Catherine M. Broome et al. profile →

Peers

Countries citing papers authored by David J. Kuter

Since Specialization

Citations

This map shows the geographic impact of David J. Kuter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Kuter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Kuter more than expected).

Fields of papers citing papers by David J. Kuter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Kuter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Kuter. The network helps show where David J. Kuter may publish in the future.

Co-authorship network of co-authors of David J. Kuter

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Kuter. A scholar is included among the top collaborators of David J. Kuter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Kuter. David J. Kuter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study 2024 ·Blood ·Nichola Cooper, David J. Kuter, Henrik Frederiksen, (unknown), (unknown), Wilma Barcellini, Joan Cid, Catherine M. Broome, (unknown), Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M. Risitano, Sangeeta Sawhney, Quentin A. Hill, Deepthi Jayawardene, (unknown), J. Zhao, Ahmed Daak	6
2	Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia 2024 ·Blood Advances ·David J. Kuter, Jiřı́ Mayer, (unknown), (unknown), Ross Baker, Zane Kaplan, Mamta Garg, Marek Trněný, Philip Choi, A.J. Gerard Jansen, Vickie McDonald, Robert Bird, Jaromír Gumulec, Milan Košťál, Terry Gernsheimer, Waleed Ghanima, Ahmed Daak, Nichola Cooper	11
3	Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria 2024 ·Hematology ·David Dingli, Carlos de Castro, (unknown), Austin Kulasekararaj, Jaroslaw P. Maciejewski, (unknown), Jens Panse, Vinod Pullarkat, Alexander Röth, Jamile M. Shammo, Louis Terriou, Ilene C. Weitz, Irina Yermilov, Sarah N. Gibbs, Michael S. Broder, David O. Beenhouwer, David J. Kuter	7
4	Avatrombopag for Adults with Early Versus Chronic Immune Thrombocytopenia 2023 ·Blood ·(unknown), Rebecca Karp Leaf, David J. Kuter, Katayoon Goodarzi, Nathan T. Connell, Jean M. Connors, Hanny Al‐Samkari	1
5	Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV) 2023 ·Blood ·Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al‐Samkari, James B. Bussel, Anna Hultberg, Filip Matthijssens, (unknown), Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland	1
6	Avatrombopag for adults with early versus chronic immune thrombocytopenia 2023 ·American Journal of Hematology ·(unknown), Rebecca Karp Leaf, David J. Kuter, Katayoon Goodarzi, Nathan T. Connell, Jean M. Connors, Hanny Al‐Samkari	6
7	Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial 2023 ·Journal of Hepatology ·David J. Kuter, Herbert L. Bonkovsky, (unknown), Gayle Ross, Encarna Guillén‐Navarro, Maria Domenica Cappellini, (unknown), Ole Hother‐Nielsen, Paolo Ventura, Gang Jia, Marianne T. Sweetser, Manish Thapar	27
8	P945: REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY 2023 ·HemaSphere ·Karthik Ramasamy, Hartmut Goldschmidt, Philippe Moreau, (unknown), David J. Kuter, Brian G.M. Durie, David Cella, Devender Dhanda, Jin Gu, (unknown), (unknown), Pallavi Patwardhan, Susan Fish, Ravi Vij	0
9	Clinical and Economic Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with TPO-Ras and Rituximab 2023 ·Blood ·David J. Kuter, (unknown), (unknown), (unknown), (unknown), (unknown), Natalia Petruski‐Ivleva	1
10	Lessons Learned Using Real‐World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia 2021 ·Clinical Pharmacology & Therapeutics ·Leah J. McGrath, Carrie M. Nielson, Bradley Saul, Alexander Breskin, (unknown), Sia Kromann Nicolaisen, (unknown), Waleed Ghanima, Christian Fynbo Christiansen, Shahram Bahmanyar, Marie Linder, Melissa Eisen, Jeffrey S. Wasser, Ivy Altomare, David J. Kuter, Henrik Toft Sørensen, Michael A. Kelsh, M. Alan Brookhart	4
11	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection breakdown → 2020 ·Blood ·Hanny Al‐Samkari, (unknown), Sunny Dzik, Jonathan Carlson, Annemarie E. Fogerty, Anem Waheed, Katayoon Goodarzi, Pavan K. Bendapudi, Larissa Bornikova, Shruti Gupta, David E. Leaf, David J. Kuter, Rachel Rosovsky	855
12	Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia 2020 ·Blood ·Catherine M. Broome, Alexander Röth, David J. Kuter, Marie Scully, Roy E. Smith, Jennifer Wang, Xiaoyu Jiang, Caroline Reuter, Ahmed Daak, William E. Hobbs	12
13	American Society of Hematology 2019 guidelines for immune thrombocytopenia breakdown → 2019 ·Blood Advances ·Cindy Neunert, Deirdra R. Terrell, Donald M. Arnold, George R. Buchanan, Douglas B. Cines, Nichola Cooper, Adam Cuker, Jenny M. Despotovic, James N. George, Rachael F. Grace, Thomas Kühne, David J. Kuter, Wendy Lim, Keith R. McCrae, Barbara Pruitt, (unknown), Sara K. Vesely	730
14	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia 2019 ·Blood ·David J. Kuter, Ralph V. Boccia, Eun‐Ju Lee, (unknown), Nikolay Tzvetkov, Jiřı́ Mayer, Marek Trněný, Milan Košťál, Roman Hájek, Vickie McDonald, (unknown), (unknown), (unknown), (unknown), Nichola Cooper	10
15	Healthcare Resource Utilization and Costs Associated with Different Treatment Modalities of Relapsed/Refractory Multiple Myeloma Patients in the US: Findings from Preamble 2017 ·Blood ·David J. Kuter, Clara Chen, (unknown), Catherine Davis, Ravi Vij	1
16	Superiority of Avatrombopag to Placebo in Increasing Platelet Counts in Patients with Chronic Liver Disease-Associated Thrombocytopenia Undergoing Scheduled Procedures: Results from 2, Phase 3 Randomized Studies 2017 ·Blood ·Norah A. Terrault, David J. Kuter, Namiki Izumi, Zeid Kayali, Paul Mitruț, Won Young Tak, Francesco Bibbiani	5
17	Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year 2017 ·Blood ·David J. Kuter, Adrian C. Newland, Beng H. Chong, Francesco Rodeghiero, (unknown), Ingrid Pabinger, Yuqi Chen, Kejia Wang, Bhakti Mehta, Melissa Eisen	1
18	Patient-Reported Symptom Burden and Peripheral Blood Counts Among Patients with Polycythemia Vera: An Analysis from the Reveal Study 2017 ·Blood ·Michael R. Grunwald, John M. Burke, David J. Kuter, Aaron T. Gerds, Brady L. Stein, Michael R. Savona, (unknown), Ahmad Naim, (unknown), Dilan Paranagama, Ruben A. Mesa	1
19	Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy 2013 ·British Journal of Haematology ·David J. Kuter, James B. Bussel, Adrian C. Newland, Ross Baker, Roger M. Lyons, Jeffrey S. Wasser, Jean‐François Viallard, Gail Macik, Mathias Rummel, Kun Nie, Susie Jun	203
20	Dabigatran 2011 ·Critical Pathways in Cardiology A Journal of Evidence-Based Medicine ·Prabashni Reddy, (unknown), (unknown), Jean M. Connors, Gregory Piazza, Caroline Block, Paul A. Arpino, Nancy Berliner, Adolph M. Hutter, Michael A. Fischer, David J. Kuter, (unknown), (unknown), (unknown), Robert P. Giugliano	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact